|

Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.

RECRUITINGPhase 2/3Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Actively Recruiting
PhasePhase 2/3
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Started2026-10-13
Est. completion2028-09-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted

Summary

The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity. The main question to answer is: What effect does Semaglutide have on body composition in adults with type 1 diabetes and overweight/obesity compared to a placebo? Around 40 participants will: * Be randomly assigned to receive semaglutide or a placebo. * Self-administer the treatment drug once per week for 24 weeks. * Complete a series of tests, measurements and questionnaires throughout the study duration. * Attend a remote follow-up visit 4 weeks after the treatment is complete.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-65 years old
* Clinical diagnosis of T1D (type 1 diabetes) for ≥ 1 year, as per clinician judgement.
* BMI (Body mass index) ≥ 27 kg/m2
* Use of multi-daily injections or insulin pump therapy.
* Use of CGM (continuous glucose monitoring).
* Agreement to the use of a highly effective method of birth control in persons of child-bearing age (if sexually active) and active avoidance of pregnancy during the trial. Child-bearing potential refers to participants of the female sex post-menarche who have not reached menopause or have a disclosed medical condition causing sterility (e.g. hysterectomy). Post-menopausal state refers to the absence of menses for 12 months without any alternative cause.
* Diabetic retinopathy assessment performed within the last 2 years, as per participant history.

Exclusion Criteria:

* Pre-existing conditions limiting physical activity, specifically inability to walk for 6 minutes.
* Active proliferative diabetic retinopathy requiring surgery or laser/injectable therapy within the last 3 months.

\*If a history of proliferative retinopathy is present within the last year, written permission from the eligible participant's ophthalmologist or optometrist is required\*

* HbA1c (glycated hemoglobin) ≥ 10% within the last 3 months.
* Current use of non-insulin anti-hyperglycemic agents within the last month.
* Severe hypoglycemic episode within the last 3 months, defined as an event where glycemia was \< 4 mmol/L, resulting in seizure, loss of consciousness, or need for third-party assistance in treatment.
* Diabetic ketoacidosis (DKA) within the last 3 months (DKA refers to the need to present to medical attention and the requirement of intravenous insulin due to ketones)
* History of bariatric surgery
* Personal history of acute/chronic pancreatitis or gallstone disease without cholecystectomy.
* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
* Severe impairment of renal function with eGFR \<30 mL/min/1.73 m2 (using CKD-EPI formula), measured within the last 12 months.
* Use of supraphysiological doses of glucocorticoids in the last 3 months, and/or expected use at some point in the next 6 months.
* Planned or ongoing pregnancy
* Breastfeeding individuals
* Prior hypersensitivity reaction to GLP1-RA (glucagon-like-peptide-1 receptor agonist)
* Clinically significant gastroparesis, defined as persistent symptoms despite pharmacotherapy such as domperidone.
* Any prior diagnostic history of eating disorder or suicidal attempts, or feelings of suicidal thoughts or behaviours in the last month\*\*
* Unstable angina, or myocardial infarction/ cardiovascular surgery / coronary stenting in the last month.
* Any serious medical or psychiatric illness likely to interfere with study participation as per the judgment of the investigator (e.g. cirrhosis, active cancer, decompensated schizophrenia).

Conditions3

DiabetesOverweight/ObesityType 1 Diabetes

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.